Skip to content
DraconiticResearch
Search Sources API
190,839 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Advanced drug delivery and PBPK modelling as translational tools for precision therapies in juvenile idiopathic arthritis

  • Marina Cuquerella-Gilabert1,2
  • Cristina Martin-Sabroso3,4
  • Javier Zarzoso-Foj1,2
  • Juan Aparicio-Blanco3,4
  • Alejandro Balsa5
  • Ana Isabel Torres-Suárez3,4
  • Víctor Mangas-Sanjuán1,2
  • Carlos Rodríguez-Nogales3,4
5 affiliations
  1. 1Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia
  2. 2Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia – University of Valencia
  3. 3Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid
  4. 4Institute of Industrial Pharmacy, Complutense University of Madrid
  5. 5Rheumatology Unit, La Paz University Hospital
Read full textPDFDOICite

Abstract

Patients with persistent forms of juvenile idiopathic arthritis (JIA) often report limited therapeutic benefit from currently available treatments. Despite substantial advances in the management of rheumatoid arthritis (RA) and related disorders over recent decades, treatment strategies for JIA remain insufficiently defined. The application of advanced drug delivery systems holds promise in addressing these limitations by enabling controlled and sustained drug release over extended periods. Other integrative approaches such as novel physiologically based pharmacokinetic (PBPK) modelling have demonstrated to be a critical tool in optimizing pharmacotherapy in pediatric populations, particularly by improving dose selection and predicting drug disposition. This review summarizes current disease-modifying antirheumatic drugs (DMARDs) for JIA management and critically examines the current, still largely prospective, integration of emerging drug delivery systems with PBPK modelling, highlighting existing translational examples alongside key opportunities and challenges for precision therapies in this field.

Related

  1. Editorial: Translational strategies for chronic lung diseases: emerging therapies and precision medicine
    Poonam Arora, Lalit Mohan Nainwal
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossref
  2. Identification and evaluation of 41 risk loci for juvenile idiopathic arthritis informs precision medicine: mechanistic implications of DNA topology and an HLA-A*02:01-ERAP2 interaction
    H. C. Ainsworth, E. S. Khvatkova, M. Sudman +25
    medRxivPreprintCC BY-NC-NDFull textHuman geneticsmedRxiv
  3. Novel Autoantibodies in Rheumatoid Arthritis: Translational Prospects from Seronegative Breakthrough to Precision Diagnosis and Treatment.
    Zewen Wu, Huijing Zhang, Jiapeng Zhang +4
    InflammationPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  4. OA24 Beyond Remission: A Multidisciplinary Approach to Transition Care in Juvenile Idiopathic Arthritis
    Rheumatology advances in practicePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. OA22 Juvenile idiopathic arthritis in transition: From childhood remission to difficult-to-treat adult disease
    Rheumatology advances in practicePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{cuquerellagilabert2026advanced,
  title = {{Advanced drug delivery and PBPK modelling as translational tools for precision therapies in juvenile idiopathic arthritis}},
  author = {Marina Cuquerella-Gilabert and Cristina Martin-Sabroso and Javier Zarzoso-Foj and Juan Aparicio-Blanco and Alejandro Balsa and Ana Isabel Torres-Suárez and Víctor Mangas-Sanjuán and Carlos Rodríguez-Nogales},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = oct,
  doi = {10.3389/fphar.2026.1917187},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1917187/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Advanced drug delivery and PBPK modelling as translational tools for precision therapies in juvenile idiopathic arthritis
AU  - Marina Cuquerella-Gilabert
AU  - Cristina Martin-Sabroso
AU  - Javier Zarzoso-Foj
AU  - Juan Aparicio-Blanco
AU  - Alejandro Balsa
AU  - Ana Isabel Torres-Suárez
AU  - Víctor Mangas-Sanjuán
AU  - Carlos Rodríguez-Nogales
PY  - 2026
DA  - 2026/10/14
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1917187
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1917187/full
AB  - Patients with persistent forms of juvenile idiopathic arthritis (JIA) often report limited therapeutic benefit from currently available treatments. Despite substantial advances in the management of rheumatoid arthritis (RA) and related disorders over recent decades, treatment strategies for JIA remain insufficiently defined. The application of advanced drug delivery systems holds promise in addressing these limitations by enabling controlled and sustained drug release over extended periods. Other integrative approaches such as novel physiologically based pharmacokinetic (PBPK) modelling have demonstrated to be a critical tool in optimizing pharmacotherapy in pediatric populations, particularly by improving dose selection and predicting drug disposition. This review summarizes current disease-modifying antirheumatic drugs (DMARDs) for JIA management and critically examines the current, still largely prospective, integration of emerging drug delivery systems with PBPK modelling, highlighting existing translational examples alongside key opportunities and challenges for precision therapies in this field.
SN  - 1663-9812
ER  -